Oxford Biomedica plc reiterated earnings guidance for the year 2024. For the year, the company expected total Group revenues of between £126 million and £134 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
331 GBX | +3.28% | +1.22% | +50.45% |
May. 09 | Avon Protection wins UK MoD supply deal; Molten Ventures up | AN |
May. 09 | Molten Ventures wins UK MoD supply contract | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.45% | 421M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- OXB Stock
- News Oxford Biomedica plc
- Oxford Biomedica plc Reiterates Earnings Guidance for the Year 2024